Search | Clinical Trials Finder

Conditions: Congenital Adrenal Hyperplasia
Interventions: virtual educational based transition intervention self-paced; Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 16 Years to 22 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Puberty, Hyperandrogenism
Interventions: Blood sampling; Other
Lead sponsor: University of Virginia; Other
Eligibility: 7 Years to 17 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
Interventions: SPI-62 dose; Drug
Lead sponsor: Sparrow Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Rochester, Minnesota • Columbus, Ohio

Conditions: Congenital Adrenal Hyperplasia
Interventions: Crinecerfont, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more

Conditions: Mild Autonomous Cortisol Secretion (MACS)
Interventions: Osilodrostat (Isturisa); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Congenital Adrenal Hyperplasia
Interventions: Tildacerfont/Placebo; Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more

Conditions: PCOS (Polycystic Ovary Syndrome), Obese Adolescents, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight Adolescents, Irregular Menstrual Cycle, Irregular Menstrual Cycles, Hirsutism, Hyperandrogenism
Interventions: Beef+; Other
Lead sponsor: Texas A&M University; Other
Eligibility: 11 Years to 17 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Disorder of Sex Development, Intersex Conditions, Congenital Adrenal Hyperplasia, Hypospadias
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more

Conditions: Polycystic Ovary Syndrome, Anovulation, Hyperandrogenism, Insulin Resistance, Glucose Intolerance, Metabolic Complication
Interventions: Placebo, Inositol; Other · Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Polycystic Ovarian Syndrome (PCOS), Irregular Menstrual Cycles, Androgen Excess
Interventions: doxycycline, Sugar Pill; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Puberty, Hyperandrogenism
Interventions: Micronized progesterone suspension, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy, Hyperinsulinemic Hypoglycemia, Familial 1, Diabetes Mellitus, Adrenoleukodystrophy, Neonatal, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Very Long Chain Acyl Coa Dehydrogenase Deficiency, Beta-ketothiolase Deficiency, Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency, Primary Hyperoxaluria Type 1, Congenital Bile Acid Synthesis Defect Type 2, Pyridoxine-Dependent Epilepsy, Hereditary Fructose Intolerance, Hypophosphatasia, Hyperargininemia, Mucopolysaccharidosis Type 6, Argininosuccinic Aciduria, Citrullinemia, Type I, Wilson Disease, Maple Syrup Urine Disease, Type 1A, Maple Syrup Urine Disease, Type 1B, Biotinidase Deficiency, Neonatal Severe Primary Hyperparathyroidism, Intrinsic Factor Deficiency, Usher Syndrome Type 1D/F Digenic (Diagnosis), Cystic Fibrosis, Stickler Syndrome Type 2, Stickler Syndrome Type 1, Alport Syndrome, Autosomal Recessive, Alport Syndrome, X-Linked, Carbamoyl Phosphate Synthetase I Deficiency Disease, Carnitine Palmitoyl Transferase 1A Deficiency, Carnitine Palmitoyltransferase II Deficiency, Cystinosis, Chronic Granulomatous Disease, Cerebrotendinous Xanthomatoses, Maple Syrup Urine Disease, Type 2, Severe Combined Immunodeficiency Due to DCLRE1C Deficiency, Thyroid Dyshormonogenesis 6, Thyroid Dyshormonogenesis 5, Supravalvar Aortic Stenosis, Factor X Deficiency, Hemophilia A, Hemophilia B, Tyrosinemia, Type I, Fructose 1,6 Bisphosphatase Deficiency, Glycogen Storage Disease Type I, G6PD Deficiency, Glycogen Storage Disease II, Galactokinase Deficiency, Mucopolysaccharidosis Type IV A, Galactosemias, Guanidinoacetate Methyltransferase Deficiency, Agat Deficiency, Glutaryl-CoA Dehydrogenase Deficiency, Gtp Cyclohydrolase I Deficiency, Hyperinsulinism-Hyperammonemia Syndrome, Primary Hyperoxaluria Type 2, 3-Hydroxyacyl-CoA Dehydrogenase Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Mitochondrial Trifunctional Protein Deficiency, Sickle Cell Disease, Beta-Thalassemia, Holocarboxylase Synthetase Deficiency, 3-Hydroxy-3-Methylglutaric Aciduria, Primary Hyperoxaluria Type 3, Hermansky-Pudlak Syndrome 1, Hermansky-Pudlak Syndrome 4, Apparent Mineralocorticoid Excess, HSDB, CBAS1, Mucopolysaccharidosis Type 2, Mucopolysaccharidosis Type 1, Severe Combined Immunodeficiency, X Linked, Severe Combined Immunodeficiency Due to IL-7Ralpha Deficiency, Diabetes Mellitus, Permanent Neonatal, Isovaleric Acidemia, Severe Combined Immunodeficiency T-Cell Negative B-Cell Positive Due to Janus Kinase-3 Deficiency (Disorder), Jervell and Lange-Nielsen Syndrome 2, Hyperinsulinemic Hypoglycemia, Familial, 2, Diabetes Mellitus, Permanent Neonatal, With Neurologic Features, Jervell and Lange-Nielsen Syndrome 1, Lysosomal Acid Lipase Deficiency, CblF, 3-Methylcrotonyl CoA Carboxylase 1 Deficiency, 3-Methylcrotonyl CoA Carboxylase 2 Deficiency, Waardenburg Syndrome Type 2A, Methylmalonic Aciduria cblA Type, Methylmalonic Aciduria cblB Type, Methylmalonic Aciduria and Homocystinuria Type cblC, MAHCD, Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency, Congenital Disorder of Glycosylation Type 1B, Mthfr Deficiency, Methylcobalamin Deficiency Type Cbl G (Disorder), Methylcobalamin Deficiency Type cblE, Usher Syndrome, Type 1B, N-acetylglutamate Synthase Deficiency, Ornithine Transcarbamylase Deficiency, Phenylketonurias, Waardenburg Syndrome Type 1, Congenital Hypothyroidism, Propionic Acidemia, Usher Syndrome, Type 1F, Pancreatic Agenesis 1, Hereditary Hypophosphatemic Rickets, Glycogen Storage Disease IXB, Glycogen Storage Disease IXC, MOWS, Epilepsy, Early-Onset, Vitamin B6-Dependent, Pyridoxal Phosphate-Responsive Seizures, Pituitary Hormone Deficiency, Combined, 1, Ptsd, Dihydropteridine Reductase Deficiency, Severe Combined Immunodeficiency Due to RAG1 Deficiency, Severe Combined Immunodeficiency Due to RAG2 Deficiency, Retinoblastoma, Multiple Endocrine Neoplasia Type 2B, Pseudohypoaldosteronism, Type I, Liddle Syndrome, Biotin-Responsive Basal Ganglia Disease, SCD, DIAR1, GSD1C, Acrodermatitis Enteropathica, Thyroid Dyshormonogenesis 1, Riboflavin Transporter Deficiency, Waardenburg Syndrome, Type 2E, SRD, Congenital Lipoid Adrenal Hyperplasia Due to STAR Deficiency, Barth Syndrome, Adrenocorticotropic Hormone Deficiency, Transcobalamin II Deficiency, Thyroid Dyshormonogenesis 3, Segawa Syndrome, Autosomal Recessive, Autosomal Recessive Nonsyndromic Hearing Loss, Thyroid Dyshormonogenesis 2A, Congenital Isolated Thyroid Stimulating Hormone Deficiency, Hypothyroidism Due to TSH Receptor Mutations, Usher Syndrome Type 1C, Usher Syndrome Type 1G (Diagnosis), Von Willebrand Disease, Type 3, Combined Immunodeficiency Due to ZAP70 Deficiency, Adenine Phosphoribosyltransferase Deficiency, Metachromatic Leukodystrophy, Canavan Disease, Menkes Disease, Carbonic Anhydrase VA Deficiency, Developmental and Epileptic Encephalopathy 2, 17 Alpha-Hydroxylase Deficiency, Smith-Lemli-Opitz Syndrome, Krabbe Disease, Glutathione Synthetase Deficiency, Mucopolysaccharidosis Type 7, Rett Syndrome, Molybdenum Cofactor Deficiency, Type A, Niemann-Pick Disease, Type C1, Niemann-Pick Disease Type C2, Ornithine Aminotransferase Deficiency, 3-Phosphoglycerate Dehydrogenase Deficiency, Leber Congenital Amaurosis 2, Dravet Syndrome, Mucopolysaccharidosis Type 3 A, Ornithine Translocase Deficiency, Carnitine-acylcarnitine Translocase Deficiency, Glucose Transporter Type 1 Deficiency Syndrome, Creatine Transporter Deficiency, Niemann-Pick Disease Type A, Pitt Hopkins Syndrome, Tuberous Sclerosis 1, Tuberous Sclerosis 2, Ataxia With Isolated Vitamin E Deficiency, Angelman Syndrome, Prader-Willi Syndrome, Homocystinuria, Permanent Neonatal Diabetes Mellitus, Transient Neonatal Diabetes Mellitus, Factor VII Deficiency, Glycogen Storage Disease Type IXA1, Glycogen Storage Disease, Type IXA2, Glycogen Storage Disease IC, Glycogen Storage Disease Type IB, Central Hypoventilation Syndrome With or Without Hirschsprung Disease
Interventions: Confirmatory Testing; Diagnostic Test
Lead sponsor: RTI International; Other
Eligibility: 1 Day to 31 Days
Enrollment: 30,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort, Cortef, Placebo; Drug · Other
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 16 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 11
States / cities: Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: AAV BBP-631; Biological
Lead sponsor: Adrenas Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Chicago, Illinois • Bethesda, Maryland • Minneapolis, Minnesota + 2 more

Conditions: Adrenal Hyperplasia, Congenital
Interventions: dexamethasone, Hydrocortisone; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 2 Years to 9 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Interventions: Metyrapone 250 mg Oral Tablets, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Congenital Adrenal Hyperplasia (CAH)
Interventions: Fludrocortisone, Hydrocortisone, Letrozole, Flutamide, Testolactone; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Polycystic Ovary Syndrome, PCOS
Interventions: Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT); Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Congenital Adrenal Hyperplasia
Interventions: Crinecerfont; Drug
Lead sponsor: Neurocrine Switzerland GmbH; Industry
Eligibility: 3 Months to 47 Months
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 8 more

Conditions: 21-hydroxylase Deficiency
Interventions: Hydrocortisone withdrawal; Procedure
Lead sponsor: Maria I. New; Other
Eligibility: 18 Years to 50 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort®, standard glucocorticoid therapy; Drug
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
Interventions: Metyrapone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort; Drug
Lead sponsor: Immedica Pharma AB; Industry
Eligibility: 16 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more

Search by objective public record fields.

A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia

Assessment of Day-night Secretion of Progesterone and LH Across Puberty

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)

Decision Support for Parents Receiving Information About Child's Rare Disease

Inositol Supplementation to Treat PCOS (INSUPP-PCOS)

Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome

Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

Early Check: Expanded Screening in Newborns

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)

Dexamethasone Treatment of Congenital Adrenal Hyperplasia

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

Insulin Differences Between African-American and Caucasian Female Adolescents With Polycystic Ovary Syndrome (PCOS)

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

Examining Genetic Differences Among People With 21-Hydroxylase Deficiency

Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia

Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia